Novavax shares jumped 16.6% to $7.84 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Markets expect rate cuts — but your earnings don’t have to suffer. Lock ...

The latest investor updates on stocks that are trending on Monday.

The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to ...

Gaithersburg’s Novavax has secured formal regulatory approval for its Covid vaccine. It's a major win, after the FDA delayed ...

Novavax Inc. drew retail attention on Friday after receiving a Biologics License Application for its COVID-19 vaccine, ...

This vaccine did previously have emergency approval by the FDA for use but can now be marketed in the U.S. for use, the ...

After a six-week long delay, The Food and Drug Administration (FDA) has finally approved a more traditional protein-based covid vaccine produced by pharmaceutical giant Novavax.

The Food and Drug Administration has granted full approval to Novavax, Inc. (NASDAQ:NVAX) COVID-19 vaccine, but with notable ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

Covid shots are facing greater scrutiny from top federal health officials like RFK Jr. and the FDA's Marty Makary.

The U.S. Food and Drug Administration approved Novavax’s Covid-19 vaccine, but limited its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.

The U.S. FDA has approved Novavax's COVID-19 vaccine, Nuvaxovid, for older adults and those aged 12 to 64 at risk of severe illness. Despite missed deadlines and regulatory challenges, the approval is ...